Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Novo Nordisk (NVO) and maintains a $160 price target.
April 01, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Novo Nordisk with a $160 price target.
The reiteration of an Overweight rating and a maintained price target of $160 by a reputable analyst suggests a positive outlook for Novo Nordisk's stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100